Dr Ahmad Fallah Tafti, MD in Midland Park, NJ - General Practice

Dr Ahmad Fallah Tafti, MD is a General Practice physician based in Midland Park, New Jersey. Dr Ahmad Fallah Tafti is licensed to practice in New Jersey (license number MA02970100) and his current practice location is 33 Central Ave, Midland Park, New Jersey. He can be reached at his office (for appointments etc.) via phone at (201) 689-0800.

NPI number for Dr Ahmad Fallah Tafti is 1942213657 and his current mailing address is 33 Central Ave, Midland Park, New Jersey. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1942213657.

Contact Information

	Dr Ahmad Fallah Tafti, MD
	33 Central Ave, Midland Park, NJ 07432
	(201) 689-0800
	(201) 689-0871

Physician's Profile

Full Name	Dr Ahmad Fallah Tafti
Gender	Male
Speciality	General Practice
Location	33 Central Ave, Midland Park, New Jersey
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1942213657
Provider Enumeration Date: 08/14/2006
Last Update Date: 04/01/2008

Medical Identifiers

Medical identifiers for Dr Ahmad Fallah Tafti such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1942213657	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	MA02970100 (New Jersey)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Ahmad Fallah Tafti is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Ahmad Fallah Tafti, MD 33 Central Ave, Midland Park, NJ 07432 Ph: (201) 689-0800	Dr Ahmad Fallah Tafti, MD 33 Central Ave, Midland Park, NJ 07432 Ph: (201) 689-0800

News Archive

New breast reconstruction surgery for women

Since her teens, Jennifer Jablon had watched family members deal with breast cancer during their 40s, 50s, and 60s. She wondered whether it would be her fate too.

New evidence-based guidelines for patients with chronic obstructive pulmonary disease

New evidence-based guidelines from the American College of Chest Physicians (ACCP) and the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) recommend a comprehensive pulmonary rehabilitation program for patients with chronic obstructive pulmonary disease (COPD), citing that pulmonary rehabilitation can help improve a patient's exercise tolerance, dyspnea, and health-related quality of life, as well as decrease hospital stay and health-care utilization.

Living longer AND living healthy

American Heart Association (AHA) President Robert A. Harrington says that the life expectancy has gone up in recent years. Still, he points out, improved life expectancy doesn't translate to improved health in all cases. According to him, "Not all those years are healthy ones as the effects of chronic illnesses are increasingly impacting the quality of life of people at a much younger age than in the past."

Teledermatology improves access to care, reduces consult time

A new study from researchers in the Perelman School of Medicine at the University of Pennsylvania and Independence Blue Cross shows that when patients' primary care doctors were able to photograph areas of concern and share them with dermatologists, the response time for a consultation dropped from almost 84 days to under five hours.

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Cardio3 BioSciences (C3BS), a leader in engineered cell-therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced the enrollment of the first patient in a Phase I clinical trial evaluating the Company's lead CAR T-Cell therapy, NKG2D CAR T-Cell, in blood cancer patients with acute myeloid leukemia (AML) or multiple myeloma (MM).

Dr Ahmad Fallah Tafti, MD - General Practice in Midland Park, NJ